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A microfluidic ExoSearch chip for multiplexed
exosome detection towards blood-based ovarian
cancer diagnosis†
Zheng Zhao,ab Yang Yang,b Yong Zeng‡*bc and Mei He‡*ad
Tumor-derived circulating exosomes, enriched with a group of tumor antigens, have been recognized as a
promising biomarker source for cancer diagnosis via a less invasive procedure. Quantitatively pinpointing
exosome tumor markers is appealing, yet challenging. In this study, we developed a simple microfluidic
approach (ExoSearch) which provides enriched preparation of blood plasma exosomes for in situ,
multiplexed detection using immunomagnetic beads. The ExoSearch chip offers a robust, continuous-flow
design for quantitative isolation and release of blood plasma exosomes in a wide range of preparation vol-
umes (10 μL to 10 mL). We employed the ExoSearch chip for blood-based diagnosis of ovarian cancer by
multiplexed measurement of three exosomal tumor markers (CA-125, EpCAM, CD24) using a training set
of ovarian cancer patient plasma, which showed significant diagnostic power (a.u.c. = 1.0, p = 0.001) and
was comparable with the standard Bradford assay. This work provides an essentially needed platform for
utilization of exosomes in clinical cancer diagnosis, as well as fundamental exosome research.
1. Introduction
Extracellular vesicles, particularly exosomes, have become
essential for intercellular communications involved in many
pathophysiological conditions, such as cancer progression
and metastasis.1–6 Exosomes are a distinct population of
small microvesicles (50–150 nm) that are released from
multivesicular bodies (MVBs) through an endolysosomal
pathway, as opposed to other subcellular membrane derived
vesicles.7,8 Studies have shown that exosomes are abundant
in cancer patient blood.9–11 Probing of tumor-derived circulat-
ing exosomes has been emerging to better aid in non-invasive
cancer diagnosis and monitoring of treatment response.12
However, exosome biogenesis at the molecular level is still
not well understood, as well as clinical utilization of exo-
somes lags, due to current technical challenges in rapid isola-
tion and molecular identification of exosomes.8,13
The most common procedure for purifying exosomes
involves a series of high-speed ultracentrifugation steps in
order to remove cell debris and pellet exosomes. However,
this procedure does not discriminate exosomes from other
vesicular structures or large protein aggregates.14–16 Moreover,
the isolation protocols are extremely tedious, time-consuming
(>10 h), and inefficient especially for blood samples, making
clinical application difficult.17–20 Although physical size is
employed to define exosomes, this property has not completely
distinguished exosomes as a specific population apart from
other vesicles that originate from different cellular locations,
such as apoptotic vesicles, exosome-like vesicles, membrane
particles, and ectosomes.5 Exosomes carry a group of specific
proteins, RNAs, and mitochondrial DNA, that represents their
cells of origin.21,22 The molecular signature of exosomes is
essential for defining exosome populations and origins.23,24
However, conventional flow cytometry for molecular marker
identification is limited by detectable size (>200 nm), thereby
excluding the majority of exosomes.25 Standard benchtop
ultracentrifugation, western blotting and enzyme-linked
immunosorbent assay (ELISA) require lengthy processes and
large amounts of purified, concentrated exosomes from blood
(~2 mL) or cell culture media (~300 mL).15,26
Herein, we developed a simple and robust microfluidic
continuous-flow platform (ExoSearch chip) for rapid exosome
isolation streamlined with in situ, multiplexed detection of
exosomes. Several microfluidic approaches have been previ-
ously developed for exosome study,27,28 such as isolation,29,30
quantification,31,32 and molecular profiling.33–35 However,
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these platforms require either complicated fabrication or
sophisticated sensing methods. We previously developed a
microfluidic system for integrated exosome lysis and detec-
tion of intravesicular protein markers that exosomes carry.28
However, on-chip isolation and enrichment of exosomes
streamlined with multiplexed detection of marker combina-
tions have not been established yet. In addition, the previous
approach involves off-chip exosome capture using a small
amount of magnetic beads and thus lacks the ability to pre-
pare large-scale enriched exosomes for variable downstream
molecular characterizations. Therefore, we developed the
ExoSearch chip which combines on-chip continuous-flow
mixing and immunomagnetic isolation with an in situ,
multiplexed exosome immunoassay. Compared to other
existing microfluidic methods, the ExoSearch chip possesses
distinct features: first, continuous-flow operation affords
dynamic scalability in processing sample volumes from
microliter for on-chip analysis to millilitre preparation for
variable downstream measurements; second, it enables
multiplexed quantification of marker combinations in one
sample with much improved speed (~40 min); lastly, because
of simplicity, cost-effectiveness and robustness, the Exo-
Search chip holds the potential to be developed into a viable
technology in point-of-care and clinical settings. The one-step
exosome assay enabled by the ExoSearch chip has been
applied for ovarian cancer diagnosis via quantifying a panel
of tumor markers from exosomes in a small-volume of blood
plasma (20 μL), which showed significant diagnostic accu-
racy and was comparable with the standard Bradford assay.
2. Experimental
2.1 ExoSearch chip fabrication and operation
The microfluidic chip was fabricated using a 10 : 1 mixture of
PDMS base and curing agent over a master wafer, and then
bound with a microscope glass slide. The master was the pat-
tern of SU8 photoresist on a 4-inch silicon wafer and was
silanized to facilitate generation of many replicas as needed.
A 2 mm magnet disk was molded into a PDMS layer during
the curing process at the desired location; the magnet is
removable for switching off magnetic force. A surface treat-
ment for the PDMS chip was applied to avoid non-specific
adsorption and generation of bubbles in the microchannel,
using a blocking buffer (2.5 w/w% BSA and 0.01 w/w%
Tween-20 in 1× PBS) with 30 min flushing at a flow rate of 1
μL min−1. A programmable syringe pump (picoliter precision)
with two 20 μL micro-syringes was used to provide the opti-
mized flow rate for continuous, on-line mixing of the plasma
sample and immunomagnetic beads. The magnetic beads
(2.8 μm, 0.1 mg mL−1) were conjugated with capture anti-
bodies for isolating intact plasma exosomes. A washing
buffer (1 w/w% BSA in 1× PBS) was applied for 5 min after
exosome capturing. A mixture of three probing antibodies
(anti CA-125/A488, anti EpCAM/A550, anti CD24/A633)
labeled with distinct fluorescent dyes was introduced after-
wards for 10 min incubation at a slow flow rate of 100 nL
min−1, followed by 5 min washing. The non-specific adsorp-
tion, specificity of probing antibodies, and incubation were
well characterized in the ESI.†
For comparison with standard benchtop approaches, dif-
ferential centrifugations were carried out on the collected
fresh frozen blood plasma (2 mL) to obtain exosomes. The
amount of protein recovered from pellets was measured by
the Bradford assay (BioRad). The exosome vesicles were con-
served at −80 °C until use. Nanoparticle tracking analysis
(NTA) was performed using NanoSight V2.3 following the
standard protocols. By monitoring the trajectory of micro-
vesicle movement, the particle numbers within the size range
of 0–500 nm were estimated in serial dilutions. The concen-
trations were calibrated back to the human plasma concen-
tration. For consistent reading, the measurement settings
were optimized and five replicas were performed to obtain
the average measurements. Transmission electron micros-
copy and image analysis were performed for characterizing
the morphology and size of the exosomes captured on the
bead surface. The agar and resin embedding protocols were
employed to ensure that the exosome morphology was maxi-
mally maintained under TEM imaging. Ultra-thin sections
(80 nm) were cut on a Leica Ultracut-S Ultramicrotome and
viewed after counterstaining in a JEOL JEM-1400 Transmis-
sion Electron Microscope operating at 80 kV. Micrographs
were prepared to a known scale, and exosome sizes were
measured and calculated using TEM imaging software with a
ruler function at 20 K magnification and normalized to the
scale bar.
2.2 Data collection and analysis
Fluorescence images were collected by an inverted epi-
fluorescence microscope with a 20× (N.A. = 0.35) Zeiss objec-
tive lens and a scientific CMOS camera (OptiMOS,
QImaging). The camera exposure time was set to 2000 ms
with a 10 MHz frequency controlled by the open source soft-
ware Micro-Manager 1.4. The filter sets of FITC, Rhodamine
and Cy-5 were used for multiplexed three-color fluorescence
detection with a LED light source for excitation. Fluorescence
image analysis was performed using ImageJ with an in-house
written Macro to determine 1000 points randomly across con-
sistent regions of bead aggregates for obtaining averaged
fluorescence intensity. Two fluorescence images were col-
lected right before and after antibody detection in three fluo-
rescence channels respectively, for calculating the difference
of fluorescence signals. The measured fluorescence signal
was then normalized to the background.
3. Results & discussion
3.1 Working principle of the ExoSearch chip
Exosomes contain a variety of surface markers originating
from their host cells.36,37 Selective isolation and specific anal-
ysis of disease-responsive exosome subpopulations is essen-
tial to evaluate the clinical relevance of circulating
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exosomes.25,38–40 To this end, the ExoSearch chip is designed
to specifically isolate exosome subpopulations and simulta-
neously measure a panel of tumor markers for better defin-
ing disease, compared to single-marker detection. As shown
in Fig. 1a, the ExoSearch chip consists of a Y-shaped injector,
a serpentine fluidic mixer for bead-based exosome capture
(~25.5 cm in length), and a microchamber (4 mm in diame-
ter) with a replaceable magnet for collection and detection of
exosomes. The microchannel is 300 μm wide and 50 μm
deep. Such a microfluidic geometry was adapted from our
previous studies on on-chip mixing and magnetic bead cap-
ture.28 The operation was simply driven by a programmable
microsyringe pump with picoliter resolution. Briefly, a
plasma sample and immunomagnetic beads were introduced
at the same flow rate from the injection channels (Fig. 1b)
through the long serpentine channel where they are uni-
formly mixed to facilitate exosome binding with the beads
(Fig. 1c). No significant aggregation of beads by interactions
with exosomes or other plasma components was observed
during flow mixing at the bead concentrations and flow rates
used here (Fig. 1b and c). Magnetic beads with bound exo-
somes can be retained as a tight aggregate in the down-
stream microchamber by magnetic force (Fig. 1d). The
amount of beads retained in the chamber was found to be
proportional to the injection volume, allowing for quantita-
tive isolation and detection of exosomes.28 A mixture of anti-
bodies labeled with unique fluorescent dyes was injected into
the chamber to stain the exosomes for multi-color fluores-
cence imaging. Total analysis is completed with as low as 20
μL plasma samples in ~40 min. Alternatively, the beads can
be released by removing the magnet and collected off the
chip to yield purified and enriched exosome samples for vari-
able benchtop measurements, such as morphological studies
by transmission electron microscopy (TEM, Fig. 1e and Fig.
S1†). While a 20 μL sample volume was used throughout this
study, the smallest sample volume that can be reliably
handled was estimated to be 10 μL, given the dead volume of
the system (i.e., syringes, tubing and the chip). Our previous
results showed that the magnetic bead aggregate formed
in the chamber increased linearly in size by a factor of 8 with
a 50-fold increase in the total injected bead number.28
Note that ~106 beads formed an aggregate of ~1 mm size.
Based on the chamber size (4 mm in diameter) and the
bead concentration used (~106 per mL), it is reasonable to
estimate that this device can readily process 10 mL of plasma
in a single continuous run. The processing capacity can be
increased by operating in a repetitive capture-and-release
manner (Fig. S1†). The single-channel device is readily scaled
up to multi-channel systems for high-throughput exosome
immuno-isolation and analysis.
3.2 Characterization of microfluidic continuous-flow mixing
for exosome isolation
We systematically characterized the on-chip mixing behaviour
of particles in various sizes for efficient exosome isolation.
First, fluorescently labeled nanoparticles (50 nm) and micro-
sized magnetic beads (2.8 μm) were flowed through the Exo-
Search chip, respectively, in order to mimic the mixing pro-
cess for exosome isolation (Fig. 2a). In both cases, two
streams were well mixed passively by the serpentine channel,
showing uniform distribution of particles across the channel
width. Mixing of fluorescently labelled exosomes with
antibody-conjugated microbeads was then studied. We
observed uniform distributions of both exosome stream and
microbeads that emitted bright fluorescence due to the bind-
ing of exosomes on the bead surface (Fig. 2a). The microbeads
were dominant for effective mixing which leads to much
faster mixing. The minimum flow travel distance required for
complete mixing in the microchannel was measured for each
case, which exhibited a linear semi-log response to the flow
rates applied (50 to 104 nL min−1) (Fig. 2b). Higher mixing
efficiency was observed at relatively low flow rates for all
three cases. Low-Reynolds-number conditions allow the exo-
somes and magnetic-bead suspension to flow side by side.
Thus, complete mixing is critical and determines the effective
residence time (incubation time), which in turn determines
the effective capture. In the serpentine microchannel, mixing
is promoted by the Dean flow and inertial lift.41 For larger
particles, the lift force increases rapidly and positions the
particles across the channel.42 Therefore, the micro-sized
magnetic beads showed faster mixing, compared to the
smaller exosomes and nanoparticles (Fig. 2a & b). In addi-
tion, in such a mixing system, the shear stress is low and par-
ticularly suitable for isolating and collecting intact exo-
somes.41,42 For all flow rates we studied (50 to 104 nL min−1),
effective mixing was completely achieved, which can signifi-
cantly reduce the incubation time for efficient
immunomagnetic capture of exosomes.43 We also investi-
gated the exosome capture efficiency by comparing the fluo-
rescence intensity of flows at the inlet and outlet of the cap-
ture chamber. The capture efficiency of 42–97.3% was
Fig. 1 (a) Workflow of the ExoSearch chip for continuous mixing,
isolation and in situ, multiplexed detection of circulating exosomes.
(b)–(c) Bright-field microscope images of immunomagnetic beads
manipulated in the microfluidic channel for mixing and isolation of
exosomes. (d) Exosome-bound immunomagnetic beads aggregated in
the microchamber with an on/off switchable magnet for continuous
collection and release of exosomes. (e) TEM image of an exosome-
bound immunomagnetic bead in a cross-sectional view.
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achieved at flow rates from 50 to 104 nL min−1 (Fig. 2c). Sub-
sequent studies were performed at the flow rate of 1 μL
min−1 which result in a fairly good capture efficiency of 72%.
This flow speed allows exosome isolation from a 20 μL
plasma sample in 20 min. For preparing enriched exosomes
from large-volume samples, the throughput can be increased
by using a relatively faster flow rate or expanding the single-
channel device to a multi-channel system. For instance, a 2
mL blood plasma can be processed within 3 hours (10 μL
min−1) without the need of manual intervention, which is at
least 3 times faster than standard ultracentrifugation for pro-
cessing the same amount of plasma with only 25% exosome
recovery rate.44
3.3 Specificity for isolating tumor-derived exosomes
Recent studies have suggested that both tumor cells and nor-
mal cells secrete exosomes, although significantly higher
amounts of exosomes have been observed from tumor cells.45
Therefore, specifically isolating, purifying and characterizing
tumor cell derived exosomes are essential.46 We characterized
the specificity for on-chip immunomagnetic isolation of exo-
somes from ovarian cancer patient blood plasma. On-chip
isolation of variable exosome subpopulations was conducted
by targeting both ovarian tumor-associated markers (EpCAM
and CA-125) and common exosomal markers (CD9, CD81,
and CD63). EpCAM is a cargo protein in exosomes and is
highly overexpressed in multiple types of carcinomas, includ-
ing ovarian tumor. CA-125 antigen is the most commonly
measured biomarker for epithelial ovarian tumors, which
accounts for 85–90% of ovarian cancer. The exosome-bound
beads were washed on the chip and then released and con-
centrated for morphology evaluation and counting of intact
exosomes using TEM, as presented in Fig. 3a. Significantly
higher amounts of round membrane vesicles (smaller than
150 nm) were observed for EpCAM+, CA-125+, and CD9+
Fig. 2 Microfluidic continuous-flow mixing for efficient exosome isolation. (a) Two-stream particle mixing in the microchannel. Left: Fluorescence
CCD images of the mixing process for a stream of Texas Red labeled nanoparticles (50 nm) co-flowed with a bead solution. Middle:
Immunomagnetic beads (2.8 μm) tracked under bright field for mixing with human blood plasma. Right: Mixing of fluorescently labeled exosomes
with antibody beads. Exosomes were purified from ovarian cancer patient plasma by ultracentrifugation. Scale bars: 300 μm. (b) Plots of the mini-
mum travel length required for uniform mixing over a flow rate range. The grey dashed line indicates the mixing channel length in the ExoSearch
chip. (c) Exosome capture efficiency as a function of the mixing flow rate measured using purified, fluorescently labeled exosomes and capture
beads. RSD is ∼5% from replicate measurements.
Fig. 3 Microfluidic ExoSearch chip for specific isolation of ovarian cancer plasma derived exosomes. (a) TEM images of on-chip
immunomagnetically isolated exosomes from ovarian cancer plasma, compared to healthy control. Scale bar is 100 nm. IgG-conjugated
immunomagnetic beads were negative control beads. (b) Exosome counts analyzed from surfaces of variable capture beads (EpCAM+, CA-125+,
CD9+, CD81+, CD63+) using TEM particle analysis (n = 25, CV = 2.8–10%). Single bead diameter was 2.8 μm and sliced bead layer was 80 nm thick.
(c) Size distribution of on-chip isolated exosomes (CD9+) using TEM particle analysis, compared to standard NTA analysis of ultracentrifugation-
purified exosomes. Dashed lines were log-normal fit (R2 > 0.98).
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subpopulations from ovarian cancer plasma, compared to
healthy controls. Negative control beads with IgG conjugation
showed negative capture of vesicles, demonstrating a good
specificity of immunomagnetic isolation. The relative expres-
sion levels of the five surface markers were measured by
counting the number of intact exosomes bound to the beads
(n = 25). The results showed a ~3–5 fold increase in expres-
sion levels of the five markers from the ovarian cancer
patient, compared to the healthy control (Fig. 3b, p = 0.001).
To verify the results of on-chip isolation, we conducted
nanoparticle tracking analysis (NTA) of ultracentrifugation-
isolated exosomes to measure their size distribution and con-
centrations. In Fig. 3c, on-chip isolated exosomes (CD9+)
exhibited a notably narrower range with the log-normal fitted
size distribution (R2 > 0.98). The smaller size than 150 nm is
a commonly used criterion to differentiate exosomes from
larger microvesicles.5 Compared to ultracentrifugation
approaches, microfluidic immunoaffinity isolation yields a
higher percentage of vesicles smaller than 150 nm (~79.7%
vs. 60.7%), suggesting that the developed ExoSearch chip
offers high specificity in isolation of circulating exosomes.
3.4 Quantitative and multiplexed exosomal marker detection
We first characterized the ExoSearch chip for quantitative iso-
lation and detection of exosomes. Fig. 4a shows the fluores-
cence images of exosomes isolated from serial dilutions of
purified, fluorescently labeled plasma exosomes. The concen-
trations of purified plasma exosomes were determined by
NTA measurements. Employing the same mixing and isolat-
ing conditions, increased fluorescence signals (ΔFL) were
observed and found to be proportional to exosome concentra-
tions. Using fluorescently labeled anti-EpCAM as the detec-
tion antibody, exosome titration curves were obtained for a
healthy plasma sample and ovarian cancer plasma, which
exhibited good linear response as seen in Fig. 4b (R2 > 0.98,
CV = ~5%). The small variation of measurements indicates
the good robustness of the method. Moreover, a much higher
ΔFL signal (~30-fold increase) was observed for the ovarian
cancer sample, compared to the healthy control under the
same concentration. These results demonstrated the ability
of the ExoSearch chip to quantitatively measure exosome sur-
face markers for differentiating changes associated with dis-
ease. The results were consistent with other recent reports
that EpCAM is highly overexpressed in ovarian tumor exo-
somes.47 The quantitative detection of intact exosomes was
achieved with a limit of detection of 7.5 × 105 particles per
mL (LOD, S/N = 3), which is 1000-fold sensitive than Western
blotting.34 While such sensitivity is comparable with that of
the previously reported microfluidic method,34 our method
features simple fabrication, easy operation and low cost.
In situ, multiplexed biomarker detection was then devel-
oped for rapid and quantitative microfluidic analysis of ovar-
ian tumor derived plasma exosomes. We chose the common
exosome marker CD9 as the capture antibody for selective
isolation of exosomes, because of the consistently high
expression of CD9 we observed from human plasma derived
exosomes (Fig. S3†). In addition to the established ovarian
cancer biomarker CA-125, human epididymis protein 4 (HE4)
has been recognized for improving the diagnostic specificity
of CA-125 in pathological tests. We did not observe substan-
tial expression of HE4 from the exosome samples (Fig. S2†),
which could be due to the different secretion pathway of
HE4.22 This observation was consistent with other recent
reports.34,48 Previous observations have indicated that CD24
could be a significant marker in ovarian tumor prognosis
and diagnosis.49 Therefore, we developed a multiplexed sand-
wich immunofluorescence assay to quantify isolated exo-
somes by targeting three markers, CA-125, EpCAM, and CD24
from the same population of exosomes, as exemplified in
Fig. 4c. Quantitative tests of raw human plasma collected
from 20 subjects (nOvCa = 15, nhealthy = 5) were conducted for
three-marker classification of ovarian tumor derived exo-
somes, and a distinctive three-marker expression pattern was
observed for ovarian cancer patients (Fig. 4d). The average
expression levels of individual exosomal markers from ovar-
ian cancer patients were statistically higher as compared to
healthy controls (CD24: 3-fold increase, p = 0.003; EpCAM:
6.5-fold increase, p = 0.0009; CA-125: 12.4-fold increase, p <
0.0001).
Non-specific adsorption of exosomes and antibody cross-
reactivity were characterized in Fig. S2.† The negative and
positive control experiments were designed and conducted in
parallel for testing the four antibodies we used in this study
(CA-125, EpCAM, CD24, and HE4). Slight auto-fluorescence of
capture beads and negligible non-specific adsorption fluores-
cence were observed, and no cross-reaction was observed
Fig. 4 (a) CCD images of bead aggregates in the ExoSearch chip
captured with fluorescence-labeled plasma exosomes in serial dilu-
tions (from left to right: 5 × 105, 1 × 106, 5 × 106, 1 × 107 particles per
mL). Scale bar was 100 μm. (b) Calibration curves for quantitative
detection of intact exosomes (R2 > 0.98, CV = ~5%). Exosomes were
purified from one healthy control plasma and one ovarian cancer
patient plasma using ultracentrifugation. Concentrations were mea-
sured by NTA. (c) CCD images of multiplexed three-color fluorescence
detection of tumor markers (CA-125, EpCAM, CD24) from captured
exosome subpopulation (CD9+). Scale bar was 50 μm, indicating the
bead aggregate size. (d) Average expression levels of three ovarian
tumor markers measured by the ExoSearch chip from 20 human sub-
jects (nOvCa = 15, nhealthy = 5). Error bars indicate standard deviations.
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between antibodies. The positive control (ovarian cancer
patient plasma exosomes) showed strong fluorescence signals
after antibody probing (CA-125, EpCAM, and CD24). However,
we did not observe an acceptable positive response from HE4
antibody probing, as HE4 is not expressed on the exosome
surface which demonstrates the negligible non-specific
adsorption onto captured exosomes (Fig. S2†). In addition,
Fig. 4d shows low signal intensities for these three markers
when their expression levels are low in healthy exosomes.
This result also indicates negligible non-specific interference
from non-specific antibody adsorption or cross-reactivity.
3.5 ExoSearch chip for blood-based ovarian cancer diagnosis
Currently, there is no single marker that can detect early-
stage ovarian cancer with desired sensitivity and specificity
(>98%).50 A large number of combinations of biomarkers
have been investigated to improve diagnostic sensitivity and
specificity.51 Circulating exosomes, enriched with a group of
tumor antigens, provide a unique opportunity for cancer
diagnosis using multi-marker combination. To this end, we
employed the ExoSearch chip for blood-based diagnosis of
ovarian cancer by simultaneously detecting three tumor anti-
gens present in the same exosome subpopulation. Standard
Bradford assay of total protein levels in ultracentrifugation-
purified exosomes from matched human subjects was
performed for parallel comparison. A total of 20 human sub-
jects (nOvCa = 15, nhealthy = 5) were chosen for evaluating diag-
nostic accuracy, based on receiver operator characteristic
analysis of adequate sample size (Table S1†). Both ExoSearch
and Bradford assay showed significantly increased level of
exosome proteins from ovarian cancer patients, compared to
healthy controls (Fig. 5a, Bradford assay p = 0.001; ExoSearch
chip p < 0.001). Particularly, the ExoSearch chip gave individ-
ual exosomal protein expression levels and the levels of CA-
125 and EpCAM showed extremely significant differences
between ovarian cancer patients and healthy controls
(EpCAM, p = 0.0009; CA-125, p < 10−4). The area under the
receiver operator characteristic curve (a.u.c.) represents the
overall accuracy of a test (Table S2†). To determine the diag-
nostic accuracy of the ExoSearch chip assay, we analyzed the
true positives (sensitivity) and false positives (one-specificity)
using receiver operating characteristic (ROC) curves. The
areas under the curves (a.u.c.) obtained for CA-125, EpCAM,
and CD24 were 1.0, 1.0 and 0.91, respectively, which were
comparable with the standard Bradford assay (a.u.c. = 1.0,
95% CI) (Fig. 5b and c). However, the diagnostic accuracy of
using exosomal particle concentrations measured by NTA was
relatively poor with an a.u.c. of only 0.67 (Fig. 5c, Fig. S4,†
95% CI). It could be attributed to the variation of NTA mea-
surement which gives a relatively large uncertainty in size
and concentration.51,52 In addition, the results were consis-
tent with recent reports showing that counting exosomes
alone was insufficient for cancer diagnosis and targeting spe-
cific exosome phenotypes could markedly improve the diag-
nostic accuracy.53 By ROC analysis (Table S3†), the ExoSearch
chip assay was highly accurate in discriminating plasma exo-
somes from ovarian cancer patients versus healthy individ-
uals. The above results suggested that the ExoSearch chip
enables sensitive multiplexed exosomal marker detection for
blood-based diagnosis of ovarian cancer with significant pre-
dictive power. The combination of plasma exosomal markers
CA-125, EpCAM, and CD24 provided desirable diagnostic
accuracy for non-invasive, early detection of ovarian cancer
(Table S3†).
4. Conclusions
Because exosomes differ 5-fold in size and 104-fold in concen-
tration in biological samples, and can contain other mem-
brane derived subcellular structures,8 accurate measurement
of exosome concentration in biofluids is challenging. For
Fig. 5 (a) Scattering plots of expression levels of three tumor markers (CA-125, p < 10−4; EpCAM, p = 0.0009; CD24, p = 0.003) from blood
plasma derived exosomes (nOvCa = 15, nhealthy = 5), compared to the standard Bradford assay of total proteins (p = 0.0013) in ultracentrifugation-
purified exosomes from matched human subjects. Black lines indicate the average expression levels of each group. Ovarian cancer patients were
represented by red dots, and healthy controls were represented by blue dots. (b) ROC analysis of the ExoSearch chip assay for in situ, multiplexed
detection of three ovarian tumor exosomal markers (CA-125 a.u.c. = 1.0, p = 0.001; EpCAM a.u.c. = 1.0, p = 0.001; CD24 a.u.c. = 0.91, p = 0.008).
Confidence interval (CI) is 95%. (c) ROC analysis of standard benchtop measurements (Bradford assay of total exosome protein, and NTA of exo-
some concentration) of blood plasma exosomes from matched patients in Fig. 5b.
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
3/
09
/2
01
6 
19
:4
1:
54
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab Chip, 2016, 16, 489–496 | 495This journal is © The Royal Society of Chemistry 2016
conventional approaches, such as NTA and flow cytometry,
exosome quantitation is limited primarily by minimum
detectable vesicle sizes, resulting in relatively large variation
(CV = ~20%).52,54 The ExoSearch chip enables simultaneous,
quantitative evaluation of multiple markers from the same
exosome subpopulation with much improved measurement
reproducibility (CV < 10%), indicating the good robustness
of this method. Such robustness is essential for precision
medicine and diagnostics involving exosomes. In addition,
the continuous-flow design affords capability for obtaining
distinct populations of exosomes from a wide range of prepa-
ration volumes (10 μL to 10 mL), which is useful for down-
stream comparative molecular profiling or therapeutic use.
As surrogates of tumor cells, exosomes hold great promise
for precise and personalized cancer diagnosis. Combinations
of exosomal protein markers may constitute a “cancer signa-
ture” and provide improved detection as the first step in mul-
timodal screening.54 However, to our best knowledge,
multiplexed assay of exosomes has not been well established
yet. We demonstrated the feasibility of ExoSearch chip for
non-invasive diagnosis of ovarian cancer using a combination
of three exosomal tumor markers (CA-125, EpCAM, CD24),
which showed comparable accuracy and diagnostic power
(a.u.c. = 1.0, p = 0.001) with the standard Bradford assay
(a.u.c. = 1.0, p = 0.0009). However, the ExoSearch chip
requires only 20 μL of human plasma for multiplexed detec-
tion of the three tumor proteins within 40 min, as com-
pared to ~1 mL of plasma and ~12 hours required by the
Bradford assay.
To date, conventional tissue biopsy for pathological diag-
nosis of ovarian cancer is extremely invasive, as a difficult
surgery. General imaging screenings, including tomography
(CT) scans and magnetic resonance imaging (MRI) scans, are
costly and unavailable in a majority of clinics. Therefore,
blood-based assay for pre-screening is highly valuable and
can dramatically decrease healthcare costs. The ExoSearch
chip provides a cost-effective, accessible approach for spe-
cific, rapid isolation of blood diagnostic exosomes, paving
the way for clinical utilization of exosomes. We will further
validate the diagnostic effectiveness of the ExoSearch chip in
various sample cohorts and enhance the disease discrimina-
tion power, including the use of large-scale sample size and
benign tumor group as a positive control. This work, as a pre-
liminary proof-of-concept in discovery phase, is an essential
step and could serve as a basic platform for developing clini-
cal tests in other diseases, as well as fundamental laboratory
research.
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